In retrospective analyses, selected cancer-associated mutations and alterations that are putative targets of sitravatinib in vitro (e.g., RET, MET, CBL, AXL, KDR, and NTRK) were monitored from circulating tumor DNA in baseline plasma samples (n = 49). This evidence concerns the gene KDR and neoplasm.